Related Experiment Video

Updated: Nov 10, 2025

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
08:51

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Published on: September 20, 2024

1.7K

Complement component 3 as biomarker of disease activity and cardiometabolic risk factor in rheumatoid arthritis and

Iván Arias de la Rosa1, Pilar Font1, Alejandro Escudero-Contreras2

  • 1Medicine Department, University of Cordoba, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), Reina Sofia University Hospital, Cordoba, Spain.

Therapeutic Advances in Chronic Disease
|April 2, 2021
PubMed

Insights

Complement component 3 (C3) is linked to increased cardiometabolic risks in rheumatoid arthritis and spondyloarthritis. Elevated C3 levels indicate higher disease activity and insulin resistance in these conditions.

Area of Science:

  • Rheumatology and Immunology
  • Cardiovascular Medicine
  • Metabolic Syndrome

Background:

  • Rheumatic diseases like rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) are associated with high cardiovascular morbidity and mortality.
  • Understanding the factors contributing to cardiovascular risk in these inflammatory conditions is crucial for patient management.

Purpose of the Study:

  • To investigate the association between complement component 3 (C3) levels and cardiometabolic risk factors.
  • To explore the relationship between C3 and disease activity in RA, PsA, and axSpA patients.

Main Methods:

  • A cross-sectional study involving 200 RA, 80 PsA, 150 axSpA patients, and 100 healthy controls.
  • Analysis of cardiometabolic risk factors, serum C3 levels, and inflammatory markers.
  • Phenotypic classification using cluster analysis and biomarker accuracy assessment via ROC curve analysis.

Main Results:

  • Significantly elevated C3 levels were observed in RA, axSpA, and PsA patients.
  • Higher C3 levels correlated with an increased prevalence of cardiometabolic risk factors and higher disease activity.
  • Complement C3 levels effectively identified insulin-resistant patients, independent of obesity.

Conclusions:

  • Complement C3 is associated with increased cardiometabolic risk factors in RA and spondyloarthritis.
  • C3 serves as a valuable biomarker for assessing insulin resistance and disease activity in these rheumatic diseases.
Abstract

Keywords:
axial spondyloarthritiscardiovascular riskcomplement C3disease activityobesitypsoriatic arthritisrheumatoid arthritis

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.6K
Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry07:20

Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry

Published on: May 19, 2020

7.4K

Related Concept Videos

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
204
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
319
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
110
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
158
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
113
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
58